Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?
Pharmaceutical Technology
JANUARY 10, 2023
On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.
Let's personalize your content